Solid Biosciences Inc.
NASDAQ:SLDBBiotechnology
+$0.27 today
- Market cap
- $695.33M
- Beta
- 2.43
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$1.75
Volume 1.13M
Average 1.39M
SLDB Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Solid Biosciences Inc.NASDAQ: SLDB
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows in line with its trailing trend
Q1 FY2026 stock-based compensation of $5.15M rose 54.2% year over year, ahead of the +52.9% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 20.7% from the prior quarter. Over 3 fiscal years it compounded at +30.9% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +54.2% holds above the trailing-twelve-month pace of +52.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 16.91M USD
- Year-over-year change
- +60.8%
- 4-year CAGR
- +6.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.91M | +60.8% |
| FY2024 | 2024-12-31 | 10.52M | +38.0% |
| FY2023 | 2023-12-31 | 7.63M | +1.2% |
| FY2022 | 2022-12-31 | 7.54M | -43.6% |
| FY2021 | 2021-12-31 | 13.37M | — |
Stock-Based Compensation vs competitors
How SLDB compares with its peers on the latest reported figures
- SLDB's LTM Mar 2026 stock-based compensation of $18.73M is the 7th largest of the 10 companies compared; the peer median is $39.28M.
- Its year-over-year change of +52.9% is the 3rd highest of 10, against a peer median of -22.0%.
- Over three fiscal years its annual growth of +30.9% compares with a peer median of +30.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.98B | +32410.1% | +56.9% | — | |
| LTM Mar 2026 | $111.37M | -39.8% | -19.1% | 5.1% | |
| LTM Jun 2026 | $84.66M | +15.0% | -12.3% | 8.4% | |
| LTM Mar 2026 | $47.93M | +107.3% | -8.3% | 60.1% | |
| LTM Jun 2026 | $39.28M | -8.1% | +44.6% | — | |
| LTM Mar 2026 | $19.48M | -28.2% | +8.7% | 22.1% | |
| LTM Mar 2026 | $18.73M | +52.9% | +30.9% | — | |
| LTM Mar 2026 | $10.03M | -22.0% | +30.6% | — | |
| LTM Mar 2026 | $3.41M | -69.9% | +124.6% | — | |
| LTM Sep 2026 | $1.76M | -94.6% | +47.1% | — | |
| Peer median (excluding SLDB) | $39.28M | -22.0% | +30.6% | 15.2% | |
Competitors are the stored peer set for SLDB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (72.19M) | (85.98M) | (96.02M) | (124.7M) | (174.33M) |
| Depreciation & Amortization | 2.96M | 2.41M | 2.58M | 2.46M | (1.87M) |
| Deferred Income Tax | 1.21M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 13.37M | 7.54M | 7.63M | 10.52M | 16.91M |
| Change in Working Capital | (23.04M) | (3.69M) | (6.34M) | 2.85M | (6.82M) |
| Accounts Receivables | (110K) | 110K | 0 | 0 | 0 |
| Inventory | (11.5M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.21M | (5.25M) | (764K) | 2.21M | (1.09M) |
| Other Working Capital | (12.64M) | 1.45M | (5.57M) | 645K | (5.73M) |
| Other Non-Cash Items | (81K) | (18.25M) | (2.03M) | 8.86M | 9.82M |
| Operating Cash Flow | (77.76M) | (97.98M) | (94.18M) | (100.01M) | (156.29M) |
| Capital Expenditures | (1.28M) | (3.02M) | (1.52M) | (654K) | (1.15M) |
| Acquisitions (Net) | 89.81M | 31.52M | 0 | 5K | 85K |
| Purchases of Investments | (141.25M) | (182.76M) | (117.43M) | (204.34M) | (235.89M) |
| Sales of Investments | 51.44M | 212.81M | 128.63M | 188.9M | 178.5M |
| Other Investing Activities | (89.81M) | 600K | 0 | 0 | 0 |
| Investing Cash Flow | (91.09M) | 59.16M | 9.69M | (16.09M) | (58.45M) |
| Debt Repayment | 0 | 2.08M | 0 | (473K) | (723K) |
| Common Stock Issued | 134.88M | 72.55M | 2.97M | 127.23M | 194.74M |
| Common Stock Repurchased | 0 | 0 | 0 | (5.11M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 107K | 203K | 148K | 794K | 425K |
| Financing Cash Flow | 134.99M | 74.83M | 3.12M | 122.44M | 194.45M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (33.87M) | 36.01M | (81.37M) | 6.34M | (20.3M) |
| Free Cash Flow | (79.05M) | (100.99M) | (95.7M) | (100.67M) | (157.44M) |
Solid Biosciences Inc.
NASDAQ:SLDB
Intrinsic Alpha fair value
Locked
Current Price
$6.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.